A Study of APG-1252 Plus Osimertinib(AZD9291) in EGFR TKI Resistant NSCLC Patients
A Study of APG-1252 Plus Osimertinib(AZD9291) in EGFR TKI Resistant NSCLC Patients
Active, not recruiting · NCT04001777 · Registry updated 2025-10-01Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study of APG-1252 Plus Osimertinib(AZD9291) in EGFR TKI Resistant NSCLC Patients | EGFR Positive Non-small Cell Lung Cancer | Active, not recruiting | Phase 1 | 2025-10-01 | NCT04001777 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Ascentage Pharma Group Inc. | 30 |
| Suzhou Yasheng Pharmaceutical Co., Ltd. | 8 |
4 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| First Hospital of Jilin University | Changchun | China | 9 |
| Henan Provincial People's Hospital | Zhengzhou | China | 44 |
| Jilin Provincial Cancer Hospital | Changchun | China | 2 |
| Sun-Yat Sen University Cancer Center | Guangzhou | China | 3 |